Novo Nordisk
Danish pharmaceutical leader in diabetes care and obesity treatments. Makers of Ozempic, Wegovy, and Rybelsus. +26% revenue growth in 2024.
Services Offered
Our Take
If you're interested in GLP-1 medications, Novo Nordisk is THE company to know - they make Ozempic, Wegovy, and Rybelsus. Their NovoCare program is absolutely essential for affording these life-changing but expensive medications. Don't pay $1,000+/month without first checking if you qualify for $0 savings cards.
Pros
- ✓Leader in diabetes/obesity
- ✓Strong patient assistance (NovoCare)
- ✓Innovative GLP-1 drugs
- ✓$0 savings cards for eligible patients
- ✓+26% revenue growth shows drug demand
Cons
- ✗GLP-1 drugs very expensive without help
- ✗Supply shortages for popular drugs
- ✗Insurance coverage varies wildly
- ✗High demand = access challenges
Pricing Details
NovoCare offers patient assistance and savings cards. Wegovy/Ozempic can be $1,000+/month without assistance, but $0 savings cards available for eligible patients.
Best For
- • Diabetes management
- • Weight loss (GLP-1)
- • Insulin needs
Coverage
- 📍 Global
Accreditations
- ✓FDA approved
- ✓EMA approved
Trust Indicators
Years in Business
101+
Last verified: December 21, 2024
⚠️ Important
Always verify pricing and details directly with the provider. Prices shown are estimates based on our research as of December 2024 and may have changed.
This information is for educational purposes only and does not constitute medical advice. Consult with qualified healthcare professionals before making medical decisions.
We may earn a commission if you use our links, but this does not affect our editorial opinions or the information presented.
Opens in new window • direct link